Nasus Pharma Ltd. (NYSEAMERICAN:NSRX – Free Report) – Stock analysts at Zacks Research issued their Q1 2026 EPS estimates for Nasus Pharma in a research report issued on Friday, May 22nd. Zacks Research analyst J. Vandermosten anticipates that the company will post earnings of ($0.27) per share for the quarter. Zacks Research also issued estimates for Nasus Pharma’s Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.85) EPS and FY2028 earnings at ($0.37) EPS.
Separately, Citizens Jmp decreased their price objective on shares of Nasus Pharma from $19.00 to $18.00 and set a “market outperform” rating for the company in a research note on Thursday, March 26th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $18.00.
Nasus Pharma Price Performance
Shares of NSRX stock opened at $3.02 on Thursday. The stock’s fifty day moving average price is $2.71. Nasus Pharma has a 12 month low of $1.98 and a 12 month high of $9.99.
About Nasus Pharma
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.
Featured Stories
- Five stocks we like better than Nasus Pharma
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Nasus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nasus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
